Sumary of EU starts real-time review of promising Sanofi-GSK COVID-19 vaccine:
- Issued on: 21/07/2021 – 08:31 Europe’s medicines agency announced on Tuesday it had began reviewing the COVID-19 vaccine developed by French pharmaceutical company Sanofi and Britain’s GlaxoSmithKline.
- Advertising Read more The decision to start the “rolling review” of the vaccine, Vidprevtyn, was based on preliminary results from lab studies and early stage clinical trials in adults, the European Medicines Agency (EMA) said in a statement.
- Late-stage global trials for the protein-based coronavirus vaccine candidate began in May.
- Sanofi and GSK hope to get approvals by the end of 2021 after early-stage results showed the vaccine produces a robust immune response.
Other COVID-19 vaccine candidates in the EU’s rolling review are those from CureVac (Germany,) Novavax (US,) Sinovac (China) and Russia’s Sputnik V, developed by the Gamaleya Center of Epidemology and Microbiology in Moscow.